Literature DB >> 25531929

Gene therapy and imaging in preclinical and clinical oncology: recent developments in therapy and theranostics.

Sebastian Gehrig1, Haider Sami, Manfred Ogris.   

Abstract

In the case of disseminated cancer, current treatment options reach their limit. Gene theranostics emerge as an innovative route in the treatment and diagnosis of cancer and might pave the way towards development of an efficacious treatment of currently incurable cancer. Various gene vectors have been developed to realize tumor-specific nucleic acid delivery and are considered crucial for the successful application of cancer gene therapy. By adding reporter genes and imaging agents, these systems gain an additional diagnostic function, thereby advancing the theranostic paradigm into cancer gene therapy. Numerous preclinical studies have demonstrated the feasibility of combined tumor gene therapy and diagnostic imaging, and clinical trials in human and veterinary oncology have been executed with partly encouraging results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531929     DOI: 10.4155/tde.14.87

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  3 in total

1.  Delivery of DNAzyme targeting aurora kinase A to inhibit the proliferation and migration of human prostate cancer.

Authors:  Zhen Xing; Sai Gao; Yan Duan; Haobo Han; Li Li; Yan Yang; Quanshun Li
Journal:  Int J Nanomedicine       Date:  2015-09-09

2.  Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo.

Authors:  Fang Wu; Yizhi Liu; Jian Li; Lei Hou; Fuxi Lei; Shangke Huang; Lu Feng; Xinhan Zhao
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

3.  Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.

Authors:  Virender Kumar; Vaibhav Mundra; Yang Peng; Yingzhe Wang; Chalet Tan; Ram I Mahato
Journal:  Theranostics       Date:  2018-07-05       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.